Advanced Synthesis in Focus - May 2025
Welcome back to the second edition of Advanced Synthesis in Focus. In this edition, you'll find compelling interviews with our in-house experts, offering their unique take on industry trends and innovations.
Ready to dive in and stay ahead? Keep scrolling to explore the latest insights, news, and expert perspectives we've curated for you!
Experts corner
Struggling with poorly soluble APIs? Allison DuRoss, Bailey Coker and Hannah Worrest share smart, sustainable approaches for tackling the challenge of poorly soluble APIs, including a material-sparing SDI (spray-dried intermediate) approach and modeling tools. They explore how to efficiently design enabled formulations that enhance bioavailability and help you reach your target dosages. Read our executive summary to discover real-world examples that illustrate how our process can help you optimize your tablet formulations.
Commercial tech transfers in OSD manufacturing
Navigate the complexities of commercial manufacturing with insights from Rebecca Peek PMP, MSBE and Laura Treche. Our paper delivers actionable strategies and highlights key challenges in Oral Solid Dosage tech transfers. Read the executive summary to learn how to streamline your process and get your product to market faster.
Driving innovation in Small-Molecule oncology drugs
Once deemed untreatable, cancer has seen a revolution in therapy, largely thanks to small-molecule drugs. This article traces their journey, from early discoveries to today's sophisticated targeted approaches like protein kinase inhibitors and ADCs. Learn how innovation continues to unlock new possibilities and how expert partners are crucial in navigating the complexities of drug development. Intrigued by the evolution of cancer treatments? Read the article here.
Noteworthy news
Your research at Lonza: win a free, fully supported experiment session with our team
Imagine pushing the boundaries of your research with access to Lonza's state-of-the-art High Throughput Experimentation (HTE) lab in beautiful Visp, Switzerland. We're offering a unique opportunity to collaborate with our expert team and bring your research ideas to life in a fully supported experiment session. Submit your research proposal now for a chance to win this incredible experience.
Lonza has strategically partnered with the CMAC (Centre for Continuous Manufacturing and Advanced Crystallisation) to supercharge its services in drug substance, drug product, particle technologies, and CMC solutions. This collaboration will allow Lonza to better serve its customers and meet the ever-evolving industry needs. Ready to explore how this collaboration can accelerate your drug substance and drug product journey? Learn more here.
Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention
Ethris and Lonza have announced their collaboration to develop spray-dried mRNA vaccines targeting respiratory diseases. This innovative approach aims to create formulations stable at room temperature, simplifying supply chains and potentially enabling needle-free nasal delivery for enhanced, localized immune responses. The initial focus is a first-in-class mRNA vaccine against influenza delivered nasally. Intrigued by the future of vaccine technology? Read the announcement to learn more about this exciting partnership!
Upcoming webinars
📅Thursday, 05 June 2025 | 16:00 CEST | 10:00 EDT
Join us to explore how solid form screening, physiologically based biopharmaceutics modeling (PBBM), and formulation maps for amorphous solid dispersions (ASDs) and salts help accelerate early-phase drug development. A model drug case study will showcase how in vitro characterization techniques and in silico modeling tools guide optimal form selection. Register here.
📅Wednesday, 25 June 2025 | 16:00 CEST | 10:00 EDT
Continuous flow techniques for pharmaceutical manufacturing at Lonza
Discover how continuous flow processes are reshaping API manufacturing. In this webinar, we’ll explore the key advantages and challenges of flow chemistry and share real case studies from Lonza’s labs that highlight its potential to reduce production costs, increase product yield and product consistency, and strengthen process robustness. Register here.
Meet our team at events in May
We appreciate your interest in the latest industry developments. Subscribe to find out first the latest news and stay tuned for more updates and insights in our future issues.
To learn more about our integrated offering in the development and manufacturing of small molecules and bioconjugates, explore our website.
CEO at xLM | Transforming Life Sciences with AI & ML | Pioneer in GxP Continuous Validation |
2wThank you for sharing this insightful edition of Advanced Synthesis in Focus. The interviews and articles highlight significant advancements in the pharmaceutical industry, particularly in addressing challenges such as poorly soluble APIs and the complexities of commercial tech transfers.